China Dasheng Biotechnology Co - Notification that Annual Report will be submitted late (NT 10-K)
30 September 2008 - 5:39AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC File
Number
333-141327
(Check One)
:
S
Form 10-K and Form 10-KSB
£
Form
20-F
£
Form
11-K
£
Form 10-Q and Form 10-QSB
£
Form
N-SAR
For
Period Ended:
June 30,
2008
[
] Transition Report on Form 10-K
[ ] Transition
Report on Form 11-K
[ ] Transition
Report on Form 10-Q
[ ] Transition
Report on Form N-SAR
For the
Transition Period Ended:
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
Part
I - Registrant Information
Full Name
of Registrant
China Dasheng Biotechnology
Company
Former
Name if Applicable _______________________________
c/o American Union
Securities Company 100 Wall Street – 15
th
Floor, New York, NY
10005
Address
of Principal Executive Office (
Street and
Number
)
City,
State and Zip Code
Part
II - Rules 12b-25(b) and (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
|
|
|
|
[
x ]
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
|
[ x
]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
|
|
[
]
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
Part
III - Narrative
State
below in reasonable detail the reasons why Form 10-K and Form 10-KSB, 20-F,
11-K, 10-Q and Form 10-QSB, N-SAR, or the transition report or portion thereof,
could not be filed within the prescribed time period. (Attach Extra Sheets
if Needed)
The
Company is unable to file its Annual Report on Form 10-K for the period ended
June 30, 2008 within the prescribed time period due to its difficulty in
completing and obtaining required financial and other information without
unreasonable effort and expense.
Part
IV - Other Information
(1)
Name and telephone number of person to contact in regard to this
notification: Peter D Zhou 212-232-0058
(2)
Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer
is no, identify report(s). Yes
[ ] No [ x ]
(3)
Is it anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof?
Yes [ ] No [ x ]
|
China Dasheng
Biotechnology Company
|
|
(Name
of Registrant as Specified in
Charter)
|
has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
September 29, 2008
By:
/s/
JiJun Qi
Name:
JiJun Qi
Title:
Chief Executive Officer and President
China Dasheng Biotechnol... (PK) (USOTC:CDBT)
Historical Stock Chart
From Jan 2025 to Feb 2025
China Dasheng Biotechnol... (PK) (USOTC:CDBT)
Historical Stock Chart
From Feb 2024 to Feb 2025
